ATM and non-small cell lung carcinoma: Through comprehensive genomic and transcriptomic analyses of patients with non-small cell lung cancer receiving anti-PD-(L)1 therapy, it was found that the survival rate of patients with ATM mutations was significantly higher than that of patients without ATM mutations65.